Skip to main content
. 2023 Sep 8;8(17):e170513. doi: 10.1172/jci.insight.170513

Figure 1. Screens of compounds activating KLF4 expression and validation experiments with SW1353 cells.

Figure 1

(A) A summary for the high-throughput screening (HTS) and the secondary screen. (B) Treatment of SW1353 cells with the compounds upregulating KLF4. Cells were treated with either of the compounds upregulating KLF4 at the tolerated doses or dimethyl sulfoxide (DMSO), and RNA was collected 24 hours after initiation of treatment. mRNA levels are expressed as mean ± SEM, relative to DMSO (n = 4 from 4 independent experiments). *P < 0.05, **P < 0.01, Dunnett’s test versus DMSO. Results of 1-way mixed-effects ANOVA test are shown in Supplemental Table 17.